Buradasınız

Anasayfa » Content

Akut Lösemili Hastalarda Anjiogenezisin Değerlendirilmesi

Evaluation of Angiogenesis in Acute Leukemia Patients

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
The importance of angiogenesis for solid tumors is well established. In contrast only few data are available for hematologic neoplasms. In our study we aimed to investigate the role of angiogenesis in bone marrow biopsies of untreated acute leukemia patients. Microvessel counts in the bone marrow biopsies of untreated patients were compared with normal controls and with ones counted at the time of complete remission. Thirteen patients were included in the study. Bone marrow samples were immunohistochemically stained with von Willebrand factor. Microvessels were scored in two areas of the highest microvessel density in sections of each bone marrow specimen. Angiogenesis was expressed as the number of vessels counted at x400 magnification. Bone marrow microvessel count was significantly increased in acute leukemia patients compared with controls (p<0,01). Additionally microvessel count at presentation was significantly higher than the one assassed at the time of complete remission (p<0,01). In conclusion by demonstrating increased angiogenesis in the bone marrow of acute leukemia patients we think that angiogenesis may play a role in the pathophysiology of acute leukemia.
Bookmark/Search this post with
Abstract (Original Language): 
Anjiogenezisin solid tümörlerdeki önemi iyi bilinmektedir. Fakat, hematolojik neoplazmlar için az sayıda veri bulunmaktadır. Çalışmamızda tedavi edilmemiş akut lösemili hastaların kemik iliklerinde anjiogenezisin rolünü araştırmayı amaçladık. Tedavi edilmemiş hastaların kemik iliğindeki mikrodamar sayıları, kontrol olgularının ve komplet remisyon dönemindeki olguların mikrodamar sayıları ile karşılaş- tırıldı. Çalışmaya on üç hasta alındı. Kemik iliği örnekleri immunohistokimyasal olarak von Willebrand faktör ile boyandı. Her kemik iliği örneğinde damar yoğunluğunun en fazla olduğu alanlardan iki tanesinde mikrodamar sayımı yapıldı. Anjiogenezis, 400’lük büyütmedeki damarların sayısı olarak ifade edildi. Kemik iliği mikrodamar sayısı akut lösemili hastalarda kontrol grubuyla karşılaştırıldığında önemli oranda artmış bulundu (p<0.01). İlaveten ilk tanıdaki mikrodamar sayısı komplet remisyon döneminde değerlendirilen damar sayısına göre önemli oranda artmış bulundu (p<0,01). Sonuç olarak; akut lösemili hastalarda kemik iliğinde anjiogenezisin artmış olduğu gösterilerek, akut lösemilerin patogenezinde anjiogenezisin rolü olabileceği kanaatine varıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-akut-losemili-hastalarda-anjiogenezisin-degerlendirilmesi.pdf
  • 2
1-6
  • Turkish

REFERENCES

References: 

1. Talks KL, Harris AL. Current status of antiangiogenic factors.
Br J Hematol 2000;109:477-89.
2. Mangi M, Newland AC. Angiogenesis and angiogenic
mediators in haematological malignancies. Br J Haematol
2000;111:43-51.
3. Folkman J. Antiangiogenic therapy. In: DeVita VT, Hellman
S, Rosenberg SA (eds). Cancer Principles&Practice of
Oncology, Fifth edition. Philadelpia:Lippincott-Raven
Publishers, 1997. 3075-85.
4. Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM.
Antiangiogenic therapy in leukemia. Acta Haematol
2001;106:190-207.
5. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L,
McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL,
Dirix LY. Quantification of angiogenesis in solid human
tumours: an international consensus on the methodology and
criteria of evaluation. Eur J Cancer 1996;32:2474-84.
6. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E,
Thomas D, Koller C, Estrov Z, O’Brien S, Keating M,
Freireich E, Albitar M. Angiogenesis in acute and chronic
leukemias and myelodsyplastic syndromes. Blood
2000;96:2240-5.
7. Belgore FM, Lip GYH, Bareford D, Wadley M, Stonelake P,
Blann AD. Plasma levels of vascular endothelial growth factor
(VEGF) and its receptor, Flt-1, in haematological cancers: a
comparison with breast cancer. Am J Haematol 2001;66:59-
61.
8. Salven P, Teerenhovi L, Joensuu H. A high pretreatment
serum vascular endothelial growth factor concentration is
associated with poor outcome in non-hodgkin’s lymphoma.
Blood 1997;90:3167-72.
9. Fiedler W, Graeven U, Ergün S, Verago S, Kilic N,
Stockschläder M, Hossfeld DK. Vascular endothelial growth
factor, a possible paracrine growth factor in human acute
myeloid leukemia. Blood 1997;89:1870-5.
10. Di Raimondo F, Palumbo GA, Molica S, Giustolisi R.
Angiogenesis in chronic myeloproliferative diseases. Acta
Haematol 2001;106:177-83.
11. Vacca A, Ribatti D, Presta M, Minischetti M, Lurlaro M, Ria
R, Albini A, Bussolino F, Dammacco F. Bone marrow
neovascularization, plasma cell angiogenic potantial, and
matrix metalloproteinase-2 secretion parallel progression of
human multiple myeloma. Blood 1999;93:3064-73.
12. Palmblad J. Angiogenesis in haematologic malignancies with
focus on multiple myeloma. Haema 2001;4:89-98. T. Özçelik, ark.
6
13. Dickson DJ, Shami PJ. Angiogenesis in acute and chronic
leukemias. Leukemia and Lymphoma 2001;42:847-53.
14. Hussong JW,Rodgers GM, Shami PJ. Evidence of increased
angiogenesis in patients with acute myeloid leukemia. Blood
2000;95:309-13.
15. Verstovsek S, Kantarjian H, Aguayo A, Manshouri T,
Freireich E, Keating M, Estey E, Albitar M. Significance of
angiogenin plasma concentrations in patients with acute
myeloid leukemia and advanced myelodysplastic syndrome.
Br J Haematol 2001;114:290-5.
16. Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M,
Maushouri T, Quackenbuch RC, Keating M, Albitar M.
Clinical significance of plasma endostatin in acute myeloid
leukemia/myelodysplastic syndrome. Cancer 2002;94:14-7.
17. Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G,
Stauder R. Blood levels of angiogenin and vascular
endothelial growth factor are elevated in myelodysplastic
syndromes and in acute myeloid leukemia. J Hematother Stem
Cell Res 2002;11:119-25.
18. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E,
Folkman J. Spectrum of tumor angiogenesis in the bone
marrow of children with acute lymphoblastic leukemia. Am J
Pathol 1997;150:815-21.
19. Padro T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J,
Büchner T, Berdel W E, Mesters RM. Increased angiogenesis
in the bone marrow of patients with acute myeloid leukemia.
Blood 2000;95:2637-44.
20. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C,
Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular
vascular endothelial growth factor is a predictor of outcome in
patients with acute myeloid leukemia. Blood 1999;94:3717-
21.
21. Kini AR, Peterson LC, Tallman MS, Lingen MW.
Angiogenesis in acute promyelocytic leukemia: induction by
vascular endothelial growth factor and inhibition by all-trans
retinonic acid. Blood 2001;97:3919-24.
22. De Bont ESJM, Rosati S, Jacobs S, Kamps WA, Vellenga E.
Increased bone marrow vascularization in patients with acute
myeloid leukemia: a possible role for vascular endothelial
growth factor. Br J Haematol 2001;113:296-304.
23. Di Raimondo F, Palumbo GA, Azzaro MP, Giustolisi R.
Angiogenesis in acute myeloid leukemia. Blood
2000;96:3656-7.
24. Greer JP, Baer MR, Kinney MC. Acute myelogenous
leukemia.In: Lee GR, Foerster J, Lukens J, Paraskevas F,
Greer JP, Rodgers GM (eds). Wintrobe’s Clinical
Hematology. 10
th
edition. Egypt:Mass Publ CO, 1999. 2288-
90.
25. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz
M, Ben-Bassat I. Therapy with thalidomide in refractory
multiple myeloma patients-the revival of an old drug. Br J
Haematol 2000;108:391-3.
26. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M,
Cherrington JM. The antiangiogenic protein kinase inhibitors
SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a
human myeloid leukemia cell line and in acute myeloid
leukemia blasts. Blood 2001;97:1413-21.

Thank you for copying data from http://www.arastirmax.com